ENVB

Enveric Biosciences, Inc.

Enveric Biosciences, Inc. (ENVB) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -2.6%
Price Return 12M -75.3%
Catalyst Signal 0.00
Market Cap $6.8M
TTM Revenue N/A
Price / Sales N/A
ROE -170.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) C+ (2.5) D+ (1.7) C- (2.1) C+ (2.6) C+ (2.5)
2026-11-04 B+ (3.7) C+ (2.5) D+ (1.7) D+ (1.8) C+ (2.7) C (2.5)
2026-10-28 B+ (3.7) C+ (2.5) D+ (1.7) D+ (1.8) C+ (2.7) C (2.5)
2026-10-21 B+ (3.7) C+ (2.5) D+ (1.7) C- (1.9) C+ (2.6) C (2.5)
2026-10-14 B+ (3.7) C+ (2.5) D+ (1.7) C (2.3) C+ (2.6) C+ (2.6)
Page 1 of 4